Primary fallopian tube adenocarcinoma: clinical complete response after salvage treatment with high-dose paclitaxel.
This Case Report describes a patient with primary fallopian tube cancer who had a late recurrence of pelvic disease following adjuvant chemotherapy for early-stage disease. Secondary cytoreductive surgery was suboptimal. The bulky residual disease was refractory to platinum-based therapy. Extension of the disease to the retroperitoneum resulted in obstructed venous return, ureteral obstruction, and renal infection. The latter necessitated a third laparotomy and a nephrectomy. Upon recovery from surgery and failure of platinum reinduction, the patient was treated with high-dose paclitaxel. The large pelvic mass regressed rapidly and completely. Current chemotherapy for fallopian tube cancer is briefly reviewed.
Tresukosol
D
D
Chulalongkorn University Hospital, Bangkok, Thailand.
Kudelka
A P
AP
Edwards
C L
CL
Fromm
G L
GL
Mante
R
R
Kavanagh
J J
JJ
D000230:Adenocarcinoma / Q000188:drug therapy*; D004305:Dose-Response Relationship, Drug; D005185:Fallopian Tube Neoplasms / Q000188:drug therapy*; D005260:Female; D006801:Humans; D008875:Middle Aged; D017239:Paclitaxel / Q000627:therapeutic use*; D016879:Salvage Therapy
D017239:Paclitaxel